Hospital

A first-in-class RNA degrader targeting MYC mRNA showed preclinical antimyeloma activity, offering a potential new strategy for targeting a historically difficult-to-drug driver of multiple myeloma.

New trials explore glucagon-like peptide-1 receptor agonists for alcohol, nicotine use disorder, and smoking cessation.

A US claims analysis found a 32% relative reduction in major adverse cardiovascular events (MACE) with tirzepatide vs a placebo-proxy comparator.

Patients with nodal TFHL had a 5.3% 5-year incidence of subsequent myeloid neoplasms, with shared TET2 mutations supporting divergent evolution from underlying clonal hematopoiesis.

A new study found that first-prescription buprenorphine abandonment nearly doubled from 2020 to 2024.

Phase 3 SOLARIS shows high-dose vitamin D3 with first-line chemo in metastatic colorectal cancer is safe—but does not significantly improve PFS.

The newly available OTC combination pairs dextromethorphan, guaifenesin, and naproxen sodium in a 12-hour formulation, creating new opportunities for pharmacist counseling on NSAID risks and duplicate therapy.

Real-world data linked semaglutide use to reduced liver stiffness and improved liver outcomes, with some benefits occurring independently of weight loss.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses how pharmacists can layer mediator-symptom management with cytoreductive or targeted therapy in systemic mastocytosis (SM) and interdisciplinary communication.

Guest Jenelle Montgomery, PharmD, BCACP, CPP, joins Erica Marini to review key updates from the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Orzeyful is the first orexin-restoring therapy for NT1, backed by the phase 3 FirstLight and RadiantLight trials.

Craig Beavers, PharmD, discusses a new American College of Cardiology expert consensus decision pathway that shifts HFpEF management from ejection fraction alone toward phenotype-driven diagnosis and treatment.

Schwartz must immediately address a measles crisis that has reached a 35-year high in the US, as well as a growing Cyclospora outbreak

In a phase 4 study, 90.9% of patients receiving preoperative suzetrigine-based multimodal therapy avoided opioid rescue after aesthetic or reconstructive surgery.

The future of 340B depends on integrating quality, compliance, technology, and pharmacist-led care to improve patient outcomes and strengthen audit readiness.

Revumenib and ziftomenib in NPM1-mutated AML: practical guidance on differentiation syndrome, QTc monitoring, and drug interactions.

A randomized trial found that medically tailored groceries cut hemoglobin A1C by 0.40 points and sharply improved food security in adults with type 2 diabetes.

Pafolacianine enables fluorescence-guided lung cancer surgery, with inpatient pharmacy integral to safe procurement, preparation, and interdisciplinary coordination.

From isotope decay to patient access, radiopharmaceuticals present unique challenges for oncology pharmacists.

A new machine learning version of the Martin-Hopkins equation matches the original's accuracy while making implementation easier for laboratories.

Suzetrigine prescriptions approached 1 million in the first half of 2026 as reimbursed access expanded, signaling growing adoption of nonopioid acute pain treatment.

A cone snail venom–derived peptide selectively inhibited the norepinephrine transporter and reduced inflammatory pain behavior without sedation in mice.

Darren Evans, PharmD, discusses what pharmacy leaders at other rural or regional health systems should consider before building a similar model.

AI-enabled scheduling, multidisciplinary coordination, and workflow redesign can help cancer centers manage growing patient volumes without compromising safety or workforce well-being.

The FDA approved once-daily centanafadine (Simtriyo), the first norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD in adults and children aged 6 years and older weighing at least 20 kg.

Predictive scheduling can improve staffing, pharmacy preparation, infusion capacity, and the overall patient experience.

July 2026 brought advances in nonopioid drug development, opioid stewardship, procedural analgesia, cancer pain, pediatric medication safety, and understanding the genetic basis of fibromyalgia.

July 2026 brought major hematology advances in gene therapy, transplantation, targeted treatments, and bleeding disorder care, alongside notable clinical trial setbacks.